A Clinical Trial to Find Out How Effective Saptanga Guggulu Is for Treating Nadi-Vrana
Phase 3
- Conditions
- Health Condition 1: L050- Pilonidal cyst and sinus with abscess
- Registration Number
- CTRI/2024/08/072265
- Lead Sponsor
- Dr Sagar Rajendra Dashpute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Pilonidal sinus of the sacrococcygeal region
Age between 19 to 29 years of both gender
No evidence of malignancy
Exclusion Criteria
Associated with malignancy
Patients with known cases of DM, HTN, TB, cardiac disorder, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of Sign and Symptoms of Nadi Vrana after intervention of Saptanga GugguluTimepoint: 55 Days
- Secondary Outcome Measures
Name Time Method Where the trial group stands in comparison with control groupTimepoint: 18 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Saptanga Guggulu's efficacy in treating Pilonidal sinus (L050)?
How does Saptanga Guggulu compare to surgical excision for Pilonidal sinus recurrence rates?
Are there specific inflammatory biomarkers predictive of Saptanga Guggulu response in Nadi-Vrana patients?
What adverse events are associated with Saptanga Guggulu in phase III trials for Pilonidal sinus?
What Ayurvedic compounds synergize with Saptanga Guggulu for enhanced Nadi-Vrana treatment outcomes?